Immunogenicity of embryonic stem cell-derived progenitors after transplantation

Current Opinion in Organ Transplantation

Volumn 16, Issue 1, 2011, Pages 90-95

  English, Karen ^a   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cell replacement therapy; embryonic stem cell derived progenitors; embryonic stem cells; immunological tolerance; transplantation rejection

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4;

ANTIGEN PRESENTATION; ARTICLE; EMBRYONIC STEM CELL; EPIGENETICS; GENE CONTROL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

ANIMALS; CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; HUMANS; IMMUNE TOLERANCE; LEUKOCYTES, MONONUCLEAR; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 78751617190     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283424faa     Document Type: Article

References (44)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145-1147.
2. Rossi SL, Nistor G, Wyatt T, et al. Histological and functional benefit following transplantation of motor neuron progenitors to the injured rat spinal cord. PLoS One 2010; 5:e11852.
3. Sharp J, Frame J, Siegenthaler M, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. Stem Cells 2010; 28:152-163.
4. Lopez MM, Valenzuela JE, Alvarez FC, et al. Long-term problems related to immunosuppression. Transpl Immunol 2006; 17:31-35.
5. Drukker M, Katz G, Urbach A, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A 2002; 99:9864-9869. (Pubitemid 34831138)
6. Li L, Baroja ML, Majumdar A, et al. Human embryonic stem cells possess immune-privileged properties. Stem Cells 2004; 22:448-456.
7. Menard C, Hagege AA, Agbulut O, et al. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet 2005; 366:1005-1012.
8. Drukker M, Katchman H, Katz G, et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 2006; 24:221-229.
9. Swijnenburg RJ, Tanaka M, Vogel H, et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005; 112:I166-I172.
10. Boyd AS, Wood KJ. Variation in MHC expression between undifferentiated mouse ES cells and ES cell-derived insulin-producing cell clusters. Transplantation 2009; 87:1300-1304.
11. Suarez-Alvarez B, Rodriguez RM, Calvanese V, et al. Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS One 2010; 5:e10192.
12. Robertson NJ, Brook FA, Gardner RL, et al. Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci U S A 2007; 104:20920-20925.
13. English K, French A, Wood KJ. Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 2010; 7:431-442.
14. Yachimovich-Cohen N, Even-Ram S, Shufaro Y, et al. Human embryonic stem cells suppress T cell responses via arginase I-dependent mechanism. J Immunol 2010; 184:1300-1308
15. Yen BL, Chang CJ, Liu KJ, et al. Brief report-Human embryonic stem cellderived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cells 2009; 27:451-456.
16. Swijnenburg RJ, Schrepfer S, Govaert JA, et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A 2008; 105:12991-12996.
17. Ma M, Ding S, Lundqvist A, et al. MHC-I expression on ESC-derived vascular progenitor cells is critical for syngeneic transplant survival. Stem Cells 2010; 28:1465-1475
18. Frenzel LP, Abdullah Z, Kriegeskorte AK, et al. Role of natural-killer group 2 member D ligands and intercellular adhesion molecule 1 in natural killer cellmediated lysis of murine embryonic stem cells and embryonic stem cellderived cardiomyocytes. Stem Cells 2009; 27:307-316.
19. Boyd AS, Wood KJ. Characteristics of the early immune response following transplantation of mouse ES cell derived insulin-producing cell clusters. PLoS One 2010; 5:e10965.
20. Foldes G, Liu A, Badiger R, et al. Innate immunity in human embryonic stem cells: comparison with adult human endothelial cells. PLoS One 2010; 5:e10501.
21. Zampetaki A, Xiao Q, Zeng L, et al. TLR4 expression in mouse embryonic stem cells and in stem cell-derived vascular cells is regulated by epigenetic modifications. Biochem Biophys Res Commun 2006; 347:89-99.
22. Lee SH, Hong B, Sharabi A, et al. Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells 2009; 27:1604-1615.
23. Hall BM, Dorsch S, Roser B. The cellular basis of allograft rejection in vivo. I. The cellular requirements for first-set rejection of heart grafts. J Exp Med 1978; 148:878-889. (Pubitemid 9034257)
24. Chidgey AP, Boyd RL. Immune privilege for stem cells: not as simple as it looked. Cell Stem Cell 2008; 3:357-358.
25. Preynat-Seauve O, de Rham C, Tirefort D, et al. Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells. J Cell Mol Med 2009; 13:3556-3569.
26. Wu DC, Boyd AS, Wood KJ. Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells 2008; 26:1939-1950.
27. Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998; 95:379-391.
28. de Jong J, Looijenga LH. Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: history and future. Crit Rev Oncog 2006; 12:171-203.
29. Dhodapkar KM, Feldman D, Matthews P, et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A 2010; 107:8718-8723.
30. Lanza RP, Chung HY, Yoo JJ, et al. Generation of histocompatible tissues using nuclear transplantation. Nat Biotechnol 2002; 20:689-696.
31. Kim K, Lerou P, Yabuuchi A, et al. Histocompatible embryonic stem cells by parthenogenesis. Science 2007; 315:482-486.
32. Kiskinis E, Eggan K. Progress toward the clinical application of patientspecific pluripotent stem cells. J Clin Invest 2010; 120:51-59.
33. Muller R, Lengerke C. Patient-specific pluripotent stem cells: promises and challenges. Nat Rev Endocrinol 2009; 5:195-203.
34. Rideout WM 3rd, Hochedlinger K, Kyba M, et al. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell 2002; 109:17-27.
35. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14:417-424.
36. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199-210.
37. Bonde S, Zavazava N. Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells 2006; 24:2192-2201.
38. Magliocca JF, Held IK, Odorico JS. Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression. Stem Cells Dev 2006; 15:707-717.
39. Verda L, Kim DA, Ikehara S, et al. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 2008; 26:381-386.
40. Tian X, Woll PS, Morris JK, et al. Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. Stem Cells 2006; 24:1370-1380. (Pubitemid 44464705)
41. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16:809-813.
42. Lui KO, Boyd AS, Cobbold SP, et al. A role for regulatory T Cells in acceptance of embryonic stem cell-derived tissues transplanted across an MHC barrier. Stem Cells 2010; 28:1905-1914.
43. Ford ML, Larsen CP. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev 2009; 229:294-306.
44. Grinnemo KH, Genead R, Kumagai-Braesch M, et al. Costimulation blockade induces tolerance to HESC transplanted to the testis and induces regulatory T-cells to HESC transplanted into the heart. Stem Cells 2008; 26:1850-1857.